z-logo
Premium
Association of HER‐2 polymorphism with Japanese sporadic prostate cancer susceptibility
Author(s) -
Yokomizo Akira,
Koga Hirofumi,
Kinukawa Naoko,
Tsukamoto Taiji,
Hirao Yoshihiko,
Akaza Hideyuki,
Mori Mitsuru,
Naito Seiji
Publication year - 2005
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20119
Subject(s) - prostate cancer , medicine , odds ratio , prostate , snp , oncology , cancer , allele frequency , breast cancer , case control study , genotype , allele , single nucleotide polymorphism , logistic regression , gastroenterology , gynecology , biology , genetics , gene
Abstract BACKGROUND Genetic polymorphisms may affect the development of prostate cancer (Pca). HER‐2 is a proto‐oncogene that has an important role in many human cancers, including Pca. To determine the association of the HER‐2 gene with Japanese sporadic Pca, we analyzed the frequency of codon 655 (A/G, isoleucine, or valine) in case and control group. METHODS We genotyped Ile 655 Val in Pca patients (n = 285) and in matched controls (n = 233). Statistical analyses were performed by Fisher's exact test and logistic regression analysis. RESULTS We observed a significantly lower frequency of the Val655 allele in the Pca patients (14.7%) compared to the control group (26.2%) ( P  = 0.0025, odds ratio (OR) = 0.476, 95% CI = 0.306–0.740). This SNP was not found to be correlated with clinical stage, PSA level, Gleason score of biopsies or age at diagnosis. CONCLUSIONS Our results indicate that the frequency of Val655 in HER‐2 was significantly lower in Japanese Pca patients, however, it was recently reported that Val655 was significant higher in breast cancer patients. This contradictory observation in prostate and breast cancer patients is interesting considering the opposite hormonal sensitivity of these two cancers. © 2004 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here